Rule 3.19A.2

# **Appendix 3Y**

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Oventus Medical Limited
ABN	12 608 393 282

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Melvyn John Bridges
Date of last notice	23 September 2021

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Interests held by: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust Parma Corporation Pty Ltd Lucille Bridges (spouse) Adinbri Super Pty Ltd atf The Bridges Super Fund
Date of change	13 October 2021

01/01/2011 Appendix 3Y Page 1

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held prior to change	Direct: 75,367 Ordinary Shares; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024 Indirect — interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares Indirect — interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 874,276 Ordinary Shares & 300,000 Options at \$0.40 ea, expiring 7 August 2025 Indirect — interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 1,687,609 Ordinary Shares & 83,335 Options exercisable at \$0.24 ea, expiring 29 June 2023 Indirect — Lucille Bridges (spouse) 358,203 Ordinary Shares
Class	Ordinary Shares
Number acquired	Indirect: Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 82,877 Ordinary Shares
Number disposed	Nil
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$9,945.24
No. of securities held after change	Direct: 75,367 Ordinary Shares; & 50,000 Options at \$0.4228 ea, expiring 8 December 2024 Indirect — interests held by Parma Corporation Pty Ltd 1,587,595 Ordinary Shares Indirect — interests held by Parma Corporation Pty Ltd as Trustee for the Bridges Family Trust 957,153 Ordinary Shares & 300,000 Options at \$0.40 ea, expiring 7 August 2025 Indirect — interests held by Adinbri Super Pty Ltd as trustee for the Bridges Super Fund 1,687,609 Ordinary Shares & 83,335 Options exercisable at \$0.24 ea, expiring 29 June 2023 Indirect — Lucille Bridges (spouse) 358,203 Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3Y Page 2 01/01/2011

Nature of change	Purchased on market
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

D ( )) 6 ( )	271
Detail of contract	Nil
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in	
relation to which the interest has changed	
Interest acquired	
-	
Interest disposed	
•	
Value/Consideration	
Note: If consideration is non-cash, provide details	
and an estimated valuation	
Interest after change	
into oct antor oriango	
	ı

## Part 3 - +Closed period

Were the interests in the securities or contracts detailed	Not in a Closed Period
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

01/01/2011 Appendix 3Y Page 3

<sup>+</sup> See chapter 19 for defined terms.